Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

22.76 -1.85 (-7.52%)
Streaming Delayed Price Updated: 2:39 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?
Via The Motley Fool
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?
12 large-cap stocks saw significant gains last week, including Summit Therapeutics, Rocket Lab, Moderna, and Netflix. Analysts raised price forecasts. 
Via Benzinga
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Summit Therapeutics Rocketed 584% in 2024
Via The Motley Fool
Where Will Summit Therapeutics Be in 5 Years?
Via The Motley Fool
How Is The Market Feeling About Summit Therapeutics?
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
3 Stocks That Could Turn $1,000 into $5,000 by 2030
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
Via The Motley Fool
Investing $5,000 in Each of These 3 Stocks at the Start of 2024 Would Have Created a Portfolio Worth More Than $100,000 Today
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher
Via The Motley Fool
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Summit Therapeutics to Present at Upcoming Investor Conferences
From Summit Therapeutics Inc.
Via Business Wire
3 Monster Stocks in the Making
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.